Nanobodies as a powerful platform for biomedicine.
作者信息
Shen Zhuolun, Sang Zhe, Shi Yi
机构信息
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Center for Protein Engineering and Therapeutics, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
出版信息
Trends Mol Med. 2022 Nov;28(11):1006-1007. doi: 10.1016/j.molmed.2022.08.007. Epub 2022 Sep 6.
Abstract
摘要
相似文献
1
Nanobodies as a powerful platform for biomedicine.纳米抗体作为生物医学的强大平台。
Trends Mol Med. 2022 Nov;28(11):1006-1007. doi: 10.1016/j.molmed.2022.08.007. Epub 2022 Sep 6.
2
The development of single-domain VHH nanobodies that target the cell surface.针对细胞表面的单域 VHH 纳米抗体的开发。
Microbiol Spectr. 2024 Nov 5;12(11):e0426923. doi: 10.1128/spectrum.04269-23. Epub 2024 Oct 7.
3
Application Progress of the Single Domain Antibody in Medicine.单域抗体在医学中的应用进展。
Int J Mol Sci. 2023 Feb 20;24(4):4176. doi: 10.3390/ijms24044176.
4
Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.SARS-CoV-2 刺突蛋白与纳米抗体结合的变构决定因素：研究突变逃逸机制和奥密克戎变体的敏感性。
Int J Mol Sci. 2022 Feb 16;23(4):2172. doi: 10.3390/ijms23042172.
5
Recent advances in the selection and identification of antigen-specific nanobodies.近期抗原特异性纳米抗体的选择和鉴定进展。
Mol Immunol. 2018 Apr;96:37-47. doi: 10.1016/j.molimm.2018.02.012. Epub 2018 Feb 22.
6
Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.结构解析三价融合前 RSV 融合蛋白疫苗候选物的骆驼源纳米抗体。
Vaccine. 2023 May 16;41(21):3308-3316. doi: 10.1016/j.vaccine.2023.04.021. Epub 2023 Apr 19.
7
Yeast surface display platform for rapid discovery of conformationally selective nanobodies.酵母表面展示平台用于快速发现构象选择性纳米抗体。
Nat Struct Mol Biol. 2018 Mar;25(3):289-296. doi: 10.1038/s41594-018-0028-6. Epub 2018 Feb 12.
8
Nanobodies as molecular imaging probes.纳米抗体作为分子成像探针。
Free Radic Biol Med. 2022 Mar;182:260-275. doi: 10.1016/j.freeradbiomed.2022.02.031. Epub 2022 Feb 28.
9
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.自适应多表位靶向和亲和力增强纳米抗体平台，用于超强、持久的抗病毒治疗。
Cell. 2024 Nov 27;187(24):6966-6980.e23. doi: 10.1016/j.cell.2024.09.043. Epub 2024 Oct 23.
10
NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model.NanoBERTa-ASP：基于预训练的 RoBERTa 模型预测纳米抗体表位。
BMC Bioinformatics. 2024 Mar 21;25(1):122. doi: 10.1186/s12859-024-05750-5.
引用本文的文献
1
Highly Potent Neutralizing Nanobodies Acting Against Chikungunya Virus Infection via Inhibiting Multiple Stages of the Viral Life Cycle.通过抑制基孔肯雅病毒生命周期的多个阶段来对抗基孔肯雅病毒感染的高效中和纳米抗体
Int J Mol Sci. 2025 Apr 23;26(9):3982. doi: 10.3390/ijms26093982.
2
A No-Brainer! The Therapeutic Potential of TRIM Proteins in Viral and Central Nervous System Diseases.显而易见！TRIM蛋白在病毒和中枢神经系统疾病中的治疗潜力。
Viruses. 2025 Apr 14;17(4):562. doi: 10.3390/v17040562.
3
Trends in nanobody technology in industrialization.纳米抗体技术的工业化发展趋势。
Discov Nano. 2025 Feb 10;20(1):23. doi: 10.1186/s11671-025-04200-2.
4
Design of Cell-Penetrating Domain Antibodies via a Genetically Encoded β-Lactam Amino Acid.通过基因编码的β-内酰胺氨基酸设计细胞穿透结构域抗体。
Angew Chem Int Ed Engl. 2025 Feb 24;64(9):e202424076. doi: 10.1002/anie.202424076. Epub 2025 Jan 15.
5
Protein-protein and protein-nucleic acid binding site prediction via interpretable hierarchical geometric deep learning.通过可解释的分层几何深度学习进行蛋白质-蛋白质和蛋白质-核酸结合位点预测。
Gigascience. 2024 Jan 2;13. doi: 10.1093/gigascience/giae080.
6
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.自适应多表位靶向和亲和力增强纳米抗体平台，用于超强、持久的抗病毒治疗。
Cell. 2024 Nov 27;187(24):6966-6980.e23. doi: 10.1016/j.cell.2024.09.043. Epub 2024 Oct 23.
7
Scalable, robust, high-throughput expression & purification of nanobodies enabled by 2-stage dynamic control.通过两阶段动态控制实现纳米抗体的可扩展、稳健、高通量表达和纯化。
Metab Eng. 2024 Sep;85:116-130. doi: 10.1016/j.ymben.2024.07.012. Epub 2024 Jul 24.
8
Radiosynthesis and preclinical evaluations of [F]AlF-RESCA-5F7 as a novel molecular probe for HER2 tumor imaging.[F]AlF-RESCA-5F7作为HER2肿瘤成像新型分子探针的放射性合成及临床前评估
Am J Nucl Med Mol Imaging. 2024 Jun 15;14(3):175-181. doi: 10.62347/BVPK1360. eCollection 2024.
本文引用的文献
1
Cilta-cel OK'd for Multiple Myeloma.西达基奥仑赛获批多发性骨髓瘤
Cancer Discov. 2022 May 2;12(5):1176. doi: 10.1158/2159-8290.CD-NB2022-0019.
2
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article.牛源抗体和骆驼源纳米抗体作为针对 SARS-CoV-2 及其变体的生物治疗武器：一篇综述文章。
Int J Surg. 2022 Feb;98:106233. doi: 10.1016/j.ijsu.2022.106233. Epub 2022 Jan 19.
3
A resource of high-quality and versatile nanobodies for drug delivery.一种用于药物递送的高质量且多功能纳米抗体资源。
iScience. 2021 Aug 21;24(9):103014. doi: 10.1016/j.isci.2021.103014. eCollection 2021 Sep 24.
4
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.白细胞介素 17A/F 纳米抗体苏内洛单抗治疗斑块状银屑病患者的多中心、随机、安慰剂对照、2b 期研究。
Lancet. 2021 Apr 24;397(10284):1564-1575. doi: 10.1016/S0140-6736(21)00440-2.
5
Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours.纳米抗体的大小和亲和力动力学影响实体瘤的靶向和穿透。
J Control Release. 2020 Jan 10;317:34-42. doi: 10.1016/j.jconrel.2019.11.014. Epub 2019 Nov 14.
6
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
7
Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.用于诊断和靶向肿瘤治疗的基于纳米抗体的递送系统。
Front Immunol. 2017 Nov 2;8:1442. doi: 10.3389/fimmu.2017.01442. eCollection 2017.
8
Nanobodies® as inhaled biotherapeutics for lung diseases.纳米抗体®作为吸入生物疗法治疗肺部疾病。
Pharmacol Ther. 2017 Jan;169:47-56. doi: 10.1016/j.pharmthera.2016.06.012. Epub 2016 Jun 29.
9
Nanobodies: natural single-domain antibodies.纳米抗体：天然单域抗体。
Annu Rev Biochem. 2013;82:775-97. doi: 10.1146/annurev-biochem-063011-092449. Epub 2013 Mar 13.
Zotero 插件